<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680680</url>
  </required_header>
  <id_info>
    <org_study_id>AUR</org_study_id>
    <nct_id>NCT00680680</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker</brief_title>
  <acronym>AUR</acronym>
  <official_title>Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franklin D. Gaylis, MD Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Franklin D. Gaylis, MD Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will&#xD;
      alleviate urinary retention secondary to BPH in who have failed a voiding trial without a&#xD;
      catheter. Following treatment with an Alpha Blocker alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urinary Retention</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males betewen the ages of 50 and 90 years of age.Written informed consent.&#xD;
&#xD;
          2. Men with acute urinary retention attributed to bladder outlet obstruction caused by&#xD;
             BPH, who have failed atleast 1 week trial of alpha blocker treatment.&#xD;
&#xD;
          3. PSA level equal to or greater than 1.5ng/ml and equal to or less than 15 ng/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Urinary retention attributed to a neurogenic or myogenic bladder dysfunction.&#xD;
&#xD;
          2. Use of psychotrophic medications.&#xD;
&#xD;
          3. Use of antichollinergic medications.&#xD;
&#xD;
          4. Prostate cancer.&#xD;
&#xD;
          5. Allery to five alpha reductase inhibitors.&#xD;
&#xD;
          6. Prior prostate surgery.&#xD;
&#xD;
          7. Urethral stricture.&#xD;
&#xD;
          8. Bladder calculi.&#xD;
&#xD;
          9. Invasive bladder cancer.&#xD;
&#xD;
         10. Inability to understand or agree with the requirements of the study.&#xD;
&#xD;
         11. Any investigational drug received within 30 days prior of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin D Gaylis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director/Sponsor</affiliation>
  </overall_official>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Franklin D. Gaylis, M.D.</name_title>
    <organization>MEDRESEARCH</organization>
  </responsible_party>
  <keyword>Urinary retention secondary to benign prostatic hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

